Sobi publishes Report for the Second Quarter 2013

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the second quarter 2013. Revenues for the quarter totalled SEK 520 M (481), an increase of 8 percent. All segments of the commercial portfolio contributed to the positive top line results in the quarter, and the pipeline programs reached several important milestones. The company reconfirmed its outlook for the year. Business Highlights * Received US Food and Drug Administration (FDA) approval to manufacture drug substance for Kineret® * Biogen Idec and Sobi presented further data from the phase 3 studies of their long-lasting haemophilia factor candidates * Completed enrolment for the Kiobrina® LAIF (Lipase Added to Infant Feeding) phase 3 study Financial Highlights * Total revenues increased by 8 percent to SEK 520.2 M (480.7) * Gross margin was 61 percent (51) for the quarter * Ended the quarter with a cash position of SEK 438.1 M * Outlook for 2013 remains unchanged "We continued to make progress across our business in the second quarter. Revenue for the overall portfolio grew by 8 percent compared to last year, with Kineret, Orfadin® and Partner Products showing strong performance at the mid- point in the year. The gross margin is evolving as expected and we are making solid progress financially with improved profitability and a stable cash position," said Geoffrey McDonough, CEO and President. "In addition, our pipeline posted several significant events including the FDA approval for the manufacture of drug substance for Kineret at Boehringer Ingelheim's site in Vienna and the release of additional data from the phase 3 trials of our long- lasting recombinant clotting factors for Haemophilia." --- Sobi's report for the second quarter 2013 can be found on http://www.sobi.com/Investors--Media/Reports/ About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with three late-stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com For more information please contact Media relations Investor relations Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor Communications Relations T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 oskar.bosson@sobi.com jorgen.winroth@sobi.com The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on July 18, 2013, at 8:00 CET [HUG#1717193]